HGH Fragment 176-191
Also known as: HGH Frag, Fragment 176-191, AOD
HGH Fragment 176-191 is a catalog-expanded peptide entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, local_seed, seed corpus peptides. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
C-terminal fragment of hGH. Claimed fat-loss action without the GH/IGF-1 anabolic effects. Most human dosing is anecdotal.
Typical cut-phase use. Limited long-term human data.
Off-cycle: 4 weeks
Timing mirrors GHRP protocols.
Contraindications
- • Pregnancy
- • Cancer history
Common side effects
- • Injection site reactions
- • Flushing
- • Mild nausea
Serious risks
- • Limited long-term safety data
Pregnancy / breastfeeding
No data — consult clinician
- Often conflated with AOD-9604 (AOD is the modified analog with a disulfide bridge)
- Not a GH agonist — does not stimulate IGF-1 or grow tissue
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.